SEC Info - Quest Diagnostics Inc. - ‘8-K’ for 4/23/24

SEC Info℠

Home

Help

Please Sign In

Quest Diagnostics Inc. – ‘8-K’ for 4/23/24

On: Tuesday, 4/23/24, at 6:47am ET · For: 4/23/24 · Accession #: 1022079-24-96 · File #: 1-12215

  As Of               Filer                 Filing    For·On·As Docs:Size

 4/23/24  Quest Diagnostics Inc.            8-K:2,9     4/23/24   11:436K

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     27K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    275K 
 6: R1          Cover                                               HTML     45K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
11: XML         XBRL Instance -- dgx-20240423_htm                    XML     13K 
 7: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- dgx-20240423_lab                      XML     62K 
 5: EX-101.PRE  XBRL Presentations -- dgx-20240423_pre               XML     33K 
 3: EX-101.SCH  XBRL Schema -- dgx-20240423                          XSD     10K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    17K 
10: ZIP         XBRL Zipped Folder -- 0001022079-24-000096-xbrl      Zip     32K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

dgx-20240423

i 0001022079 i false00010220792024-04-232024-04-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM i 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): i April 23, 2024

i Quest Diagnostics Incorporated

(Exact Name of Registrant as Specified in Its Charter)

i Delaware

(State or other jurisdiction of incorporation)

i 001-12215

i 16-1387862

(Commission File Number)

(I.R.S. Employer Identification No.)

i 500 Plaza Drive

i Secaucus,

i NJ

i 07094

(Address of principal executive offices)

(Zip Code)

i (973)

i 520-2700

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, $0.01 Par Value	i DGX	i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

On April 23, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits


d.	Exhibit

	99.1	Press release of Quest Diagnostics Incorporated dated April 23, 2024, announcing, among other things, its results for the quarter ended March 31, 2024.



	104	The cover page from this current report on Form 8-K, formatted in Inline XBRL.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

April 23, 2024


QUEST DIAGNOSTICS INCORPORATED

By:			/s/ *Sean D. Mersten*
			Sean D. Mersten
			Vice President and Corporate Secretary

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	4/23/24	None on these Dates
	3/31/24
		List all Filings

↑Top

Filing Submission 0001022079-24-000096 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)